Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study

Overview of attention for article published in Journal of Rheumatology, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 1 blog post.

For a study, researchers sought to compare the effectiveness of secukinumab (SEC) 300 mg and 150 mg against a placebo in a…